🔎 Trials Near Me

Acasă › Boala Crohn › Indiana

Studii clinice pentru Boala Crohn în Indiana

13 studii pentru Boala Crohn caută participanți în Indiana.

Orașe în Indiana

Text oficial al studiului (în engleză)

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  • Indiana University Health University Hospital ( Site 5022), Indianapolis
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 2 oct. 2026 · NCT06430801

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastroenterology Health Partners /ID# 284145, New Albany
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT07697456

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  • Indiana University Health University Hospital /ID# 278129, Indianapolis
În curs de recrutareFaza 2
Vârste de la 18 la 75 · Toate sexele · Actualizat 25 sept. 2026 · NCT06548542

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

  • IU Health University Hospital, Indianapolis
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT07196722

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • Riley Hospital for Children, Indianapolis
În curs de recrutareFaza 3
Vârste de 3 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06663332

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

  • Indiana University Health University Hospital, Indianapolis
  • Gastroenterology Health Partners, New Albany
În curs de recrutareFaza 3
Vârste de la 18 la 70 · Toate sexele · Actualizat 24 sept. 2026 · NCT06937099

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 23 sept. 2026 · NCT07184931

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

  • Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
În curs de recrutareFaza 3
Vârste de la 16 la 80 · Toate sexele · Actualizat 23 sept. 2026 · NCT07184944

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

  • Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
În curs de recrutareFaza 3
Vârste de la 2 la 17 · Toate sexele · Actualizat 23 sept. 2026 · NCT05995353

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

  • Riley Childrens Hospital, Indianapolis
În curs de recrutareFaza 3
Vârste de la 2 la 17 · Toate sexele · Actualizat 24 aug. 2026 · NCT05509777

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

  • Indiana University Health Riley Hospital for Children /ID# 262215, Indianapolis
În curs de recrutareFaza 3
Vârste de la 2 la 17 · Toate sexele · Actualizat 24 iun. 2026 · NCT06332534

Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease

  • Riley Hospital for Children at Indiana University Health, Indianapolis
În curs de recrutareFaza 4
Vârste de la 6 la 17 · Toate sexele · Actualizat 27 mai 2026 · NCT05781152

Precise Infliximab Exposure and Pharmacodynamic Control

  • Riley Hospital for Children, Indianapolis
În curs de recrutareFaza 2/3
Vârste de la 6 la 22 · Toate sexele · Actualizat 5 mai 2026 · NCT05660746

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.